electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
electroCore, Inc. to report Q3 2023 financial results on November 8, 2023
Positive
Investors can expect electroCore's Q3 2023 financial results after the market close on November 8, 2023.
10/09/2023 - 08:00 AM
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.
Wednesday, November 8, 2023, 4:30 PM EST located here electroCore Earnings Webcast
About electroCore, Inc.
For more information, visit www.electrocore.com .
Contact:
When will electroCore report its Q3 2023 financial results?
electroCore will report its Q3 2023 financial results on November 8, 2023.
What time will electroCore's conference call and webcast take place?
electroCore's conference call and webcast will take place at 4:30 PM EST on November 8, 2023.
How can I access the conference call?
You can access the conference call by dialing 877-407-8835 (Domestic) or the international number provided in the PR. The conference ID is 13739201.
Will there be a webcast of the conference call?
Yes, electroCore will provide a webcast of the conference call. You can access it through the 'electroCore Earnings Webcast' link provided in the PR.
ECOR Rankings
#411 Ranked by Stock Gains
ECOR Stock Data
Industry
Electromedical and Electrotherapeutic Apparatus Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Electromedical and Electrotherapeutic Apparatus Manufacturing
Country
United States
About ECOR
electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.
